There was very low influenza activity from June to August 2020 in the Southern Hemisphere.
During the upcoming flu season, it is essential to ensure a high coverage rate of vaccination, particularly among populations who are vulnerable to COVID-19.
The efficacy and safety of pimodivir, an inhibitor of influenza virus polymerase basic protein 2, was being investigated in two phase 3 studies.
Acute heart failure and acute ischemic heart disease are most common cardiovascular events in adults hospitalized with influenza.
A school-located influenza vaccination intervention is associated with a reduction in the incidence of influenza hospitalization.
The ACIP has issued new guidelines for the prevention and control of seasonal influenza with vaccines for the 2020–2021 season.
Influenza vaccinations were found to be underutilized among groups who are considered to be at high risk for complications from infection.
Influenza vaccination appears lower at US dialysis facilities with higher proportions of Black and Hispanic patients.